# Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.

> **NCT05002530** · PHASE4 · UNKNOWN · sponsor: **Kafrelsheikh University** · enrollment: 10000 (estimated)

## Conditions studied

- Post COVID-19 Anosmia (Loss of Smell)

## Interventions

- **DRUG:** Aerosolized 13 cis retinoic acid plus Vitamin D
- **DRUG:** Aerosolized All trans retinoic acid plus Vitamin D
- **OTHER:** Standard therapy

## Key facts

- **NCT ID:** NCT05002530
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11
- **Primary completion:** 2021-12
- **Final completion:** 2022-01
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2021-11-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002530, "Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05002530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*